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Abstract: The success of any surgical procedure is based on adequate hemostasis. Many 
different biomaterial products can be used to achieve that aim. The products that can be used 
during surgery may be classified as topical hemostats, sealants, and adhesives. Hemostats can 
clot blood. Sealants can create sealing barriers. Adhesives bond tissue together. Collagen, 
gelatin, and cellulose are hemostat agents. TachoSil® is a development of TachoComb® and 
TachoComb® H. TachoComb is made with equine collagen, bovine thrombin, bovine aprotinin, 
and human fibrinogen. The clinical efficacy of TachoSil was shown firstly by a clinical study 
of hepatic surgery. In the study, TachoSil proved to be superior to argon beamer in obtaining 
effective and fast intraoperative hemostasis. Following the study, many applications in different 
fields of surgery have been reported in the literature. The use of TachoSil in open abdominal 
surgery and its relevant results have encouraged the use of TachoSil in laparoscopic surgery. 
Unfortunately, its use in laparoscopy has not become as popular as it is in open surgery, due 
to a lack of efficacious techniques. Immunologic reactions to compounds of TachoSil and the 
transmission of infectious diseases are two major risks concerning topical hemostasis. Even 
though the risk of severe immunologic reactions to bovine material is low, TachoSil has gradu-
ally replaced all bovine material with material of human origin and has therefore eliminated the 
associated risks of bovine material. TachoSil has a good satisfaction rate among surgeons and 
reduces both the operating time for patients and the time spent in intensive care units.
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Introduction
The success of any surgical procedure is based on adequate hemostasis.1 Ineffective 
local hemostasis is the major cause of bleeding during surgery, but many other causes 
may be involved. Major bleeding can be controlled by standard surgical techniques, 
such as stitches, ligatures, or clips. Chemical, thermal, and mechanical procedures can 
be used during surgery to achieve hemostasis, especially when diffuse hemorrhages 
occur. Surgical tools such as electrocautery, argon beamer, or laser are often useful, but 
sometimes these methods do not achieve satisfying results. Many different biomaterial 
products can be used to achieve that aim.2
Hemostatic agents
The products that can be used during surgery may be classified as topical hemo-
stats, sealants, and adhesives.3 Hemostats can clot blood. Sealants can create seal-
ing   barriers. Adhesives bond tissue together. Collagen, gelatin, and cellulose are 
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Collagen is derived from bovine collagen. As with all 
bovine collagen products, it contains a small amount of 
bovine serum protein, so it should not be used in patients 
who are allergic to this product. Collagens exist as sponges 
of various sizes or in syringes. The most commonly used 
hemostatic collagens include FloSeal® (Baxter, Zurich, 
Switzerland), TissuFleece® (Baxter, Zurich, Switzerland), 
and GentaFleecel® (Baxter, Zurich, Switzerland).2 Gelatin 
sponges are a protein mixture obtained from collagen and 
Spongostan® (Johnson & Johnson, North Yorkshire, UK)/
Surgifoam® (Ethicon 360 Somerville, NJ, USA) and are a 
diffuse product. Oxidized celluloses are derived from cotton 
cellulose and can be provided in single or multiple sheets. 
In addition to the mechanical effect, the cellulosic acid 
within the product facilitates hemostasis by   denaturating 
blood proteins. The most commonly commercial agent 
used in this group is Surgicel® (Ethicon 360 Somerville, 
NJ, USA).2 Fibrin glue is an example of a sealant com-
posed of a fibrinogen concentrate and thrombin solutions. 
Thrombin solutions are currently divided into two categories: 
commercial products and those created in the laboratory. 
Tissucol® (Baxter, Zurich, Switzerland), Tisseel® (Baxter, 
Zurich, Switzerland), Beriplast® (Nycomed Linz, Austria), 
TachoSil® (Nycomed Linz, Austria),  and Quixil® (Omrix, 
Rhode-St-Genese, Belgium) are the most commonly used 
commercial products.4 The cyanoacrilates are a group of 
fast-acting adhesives that are currently approved for topical 
external use.
Design, composition, and action  
of TachoSil
TachoSil is a development of TachoComb® (Nycomed Linz, 
Austria) and TachoComb® H (Nycomed Linz, Austria). TachoC-
omb is made with equine collagen, bovine thrombin, bovine 
aprotinin, and human fibrinogen. TachoComb H contains 
human thrombin in place of bovine thrombin. TachoSil contains 
only human fibrinogen with equine collagen as a   carrier. It does 
not contain aprotinin or any other component of bovine origin. 
TachoSil works by mimicking the final steps of the natural 
blood-clotting process, creating a fibrin clot at the surgical site 
to achieve hemostasis in 3–5 minutes. TachoSil consists of a 
white collagen sponge coated on one side with fibrinogen and 
thrombin. Riboflavin gives a yellow appearance to the coated 
side (Figure 1). One of the most important achievements of 
TachoSil compared with its precursors is the possibility of stor-
age at room temperature, avoiding the necessity of refrigeration 
or freezing. The product is ready to use, which represents an 
advantage when it has to be used quickly.
TachoSil becomes active when the product comes into 
contact with bleeding or leaking tissue. The dry coating 
  dissolves and releases the coagulation factors fibrinogen and 
thrombin and initiates the final steps in the blood coagulation 
process. During this process, thrombin converts fibrinogen 
into fibrin monomers, which spontaneously polymerize, and 
endogenous factor XIII catalyzes the crosslinking of fibrin, 
creating a firm, mechanically stable network. The resulting 
fibrin clot ensures effective hemostasis and sealing, thus 
preventing leaks. When the patch is in the appropriate place, 
the honeycomb-like matrix of the sponge folds in, resulting 
in air- and liquid-tight sealing of the tissue. TachoSil will 
be enzymatically degraded and safely absorbed by the body 
within 12 weeks of application.
TachoSil is indicated not only for hemostasis but also 
to provide tissue sealing, to support sutures, to prevent 
adhesions and erosions, to protect nerves, and to occlude 
structures such as bronchioles, lymph vessels. or bile 
ducts.
The sourcing of human coagulation factors of TachoSil 
is controlled and processed according to World Health 
  Organization regulations, which provide a high degree of 
safety against human pathogens, including HIV and hepatitis 
C virus. Allergic reactions or cellular/humoral immunity 
  following surgical implantation to purified collagen as formu-
lated in TachoSil have never been detected. Equine collagen 
is a solid, rod-shaped molecule that is free of immunogenic 
epitopes. There are no registered reports on immunologic 
reactions to the equine collagen.
TachoSil is contraindicated in patients with hypersensitiv-
ity to any of the active substances or any of the excipients. 
Figure 1 The yellow section represents the active part of TachoSil that has to be 
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It should be administered to pregnant or lactating women 
only if it is clearly necessary.
Clinical application in abdominal 
surgery
Hepatic surgery
The clinical efficacy of TachoSil was shown by a clinical study 
of hepatic surgery.5 It was the first prospective,   randomized, 
open, controlled, multicentre trial with   intraoperative as well as 
postoperative assessment of efficacy and a 1-month follow-up 
period of two groups of patients requiring secondary hemostasis 
during planned liver resection. The first group of patients was 
treated using carrier-bound fibrin sealant, and the second group 
was treated using argon beamer. The results showed a significant 
superiority of TachoSil over argon beamer regarding the time 
of hemostasis. In the study, TachoSil proved to be superior to 
argon beamer in obtaining effective and fast intraoperative 
hemostasis. After the study, many applications in different fields 
of surgery have been reported in the literature.
In the field of hepatic surgery, a second recent trial has been 
performed to demonstrate the efficacy and safety of TachoSil 
versus argon beamer in liver resection.6 The primary endpoint of 
the international, multicenter, randomized, controlled, surgical 
trial was the hemostasis time after starting the randomized inter-
vention to obtain secondary hemostasis. Secondary endpoints 
were drainage duration, volume, and content. In the two groups 
of patients, the mean hemostasis time was less when TachoSil 
was used (3–6 minutes)   compared with argon beamer (5.0 min-
utes P = 0.008). Postoperative drainage volume, drainage fluid, 
and drainage duration did not differ between the two groups. 
The study confirmed that TachoSil hemostasis is significantly 
faster than argon beamer after liver resection.
Another clinical trial supports the use of TachoSil. In the 
study, 115 patients were distributed into groups for major 
and minor hepatectomies, with or without application of a 
carrier-bound collagen sponge on the raw surface of the liver. 
Postoperative mortality, incidence and severity of postopera-
tive surgical complications, and length of hospital stay were 
the main outcome measures. Postoperative drainage output 
volume, transfusion requirements, and changes in biochemi-
cal parameters were the secondary outcome measures. The 
fibrin sealant after major liver resection was effective in 
decreasing drainage volume, postoperative blood transfusion, 
complications, and hospital stay.7 To facilitate the decrease of 
drainage output volume, a “new Glisson surface” on resected 
liver should be made by a fibrin sealant. Therefore, all the 
liver surface should be sealed starting 1–2 cm above Glisson 
of the cut surface (Figure 2).8
Two experimental studies have focused on two different 
aspects of the product. In an experimental liver resection 
model in pigs by Erdogan et al,9 the application of a collagen 
patch on the resection surface was as effective as liquid fibrin 
sealants in obtaining hemostasis and sealing biliary ducts, but 
the adhesive strength of the sponge on the resection surface 
was superior. In particular, in this experimental study, the 
sealant increased pressure in the biliary system by infusing a 
saline solution with an automatic pump through a catheter in 
the common bile duct. This condition mimics the same effects 
that bile or blood has on the collagen sponge surface during 
the postoperative days, but it is condensed in a few minutes, 
and the pressure achieved inside the bile ducts is much higher 
than in clinical conditions (up to 120 mm Hg). The pressure 
in the biliary system was recorded and the resection surface 
was examined to identify leakage. The fibrinogen-coated col-
lagen patch showed that the adhesive dressing always became 
loose, with the fleece material lifting off at the sealing level, 
but no bleeding or bile leakage was observed.
A second, more recent, experimental study investigated 
the efficacy of TachoSil in stopping severe bleeding in a 
coagulopathic pig model with blunt liver injury.10 The study 
analyzed two groups of pigs that were previously prepared by 
splenectomy and cystotomy and by inducing coagulopathy. 
Subsequently, a grade III liver injury was induced. At this point, 
animals were randomly assigned to receive a placebo patch or 
TachoSil. Coagulation parameters and hemodynamic variables 
as well as the chosen treatment were monitored for 2 hours after 
injury and patch placement. All animals treated with TachoSil 
survived, whereas 100% of the control group died before reach-
ing the end of the observation period (P , 0.001).
A clinical report on liver transplantation has also been 
published.11 As bile leaks are a frequent complication of 
Figure 2 TachoSil correctly placed on the liver surface after hepatic resection.Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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adults after liver transplantation, the authors compared   
surgical complications in patients who had the cut surface of 
the donor liver treated with a patch with those in whom the cut 
surface of the liver was treated with fibrin glue. The results 
of the study show that using a fibrinogen collagen sponge 
patch may reduce bile leaks from the cut surface of the liver 
during adult right lobe split liver transplantation.
Finally, in the field of hepatic surgery, TachoSil has 
also been used for life-threatening bleeding from a portal 
vein anastomosis during a cadaveric liver transplantation.12 
A massive hemorrhage was seen in the area of the portal 
anastomosis after declamping, and control was achieved by 
application of the TachoSil patch around the portal vein. In 
this case, the role of the surgeons in applying slight finger 
pressure for several minutes was crucial. In fact, it is impor-
tant to note that once the patch is in place, it should not be 
replaced or removed.
Pancreatic surgery
Many fields of abdominal surgery use this device because 
it is effective in hemostasis and also prevents leakage. Pan-
creatic surgery is one of the most difficult surgical fields 
due to the risk of pancreatic fistula. Two clinical studies 
concerning pancreatic surgery and the use of precursors 
of TachoSil have been reported in the literature. The first 
of these studies concerns patients submitted to surgery 
for acute pancreatitis, pancreas carcinoma, and chronic 
pancreatitis.13 The second study compares two groups of 
patients in whom the distal pancreatic stump after pancre-
atic resection has been treated using suture or stapler for 
closure with TachoComb in almost 50% of both groups. 
Both studies have small sample sizes, and no conclusive 
data are provided about the efficacy of the sealant agent in 
preventing pancreatic fistula.
Recently, a manuscript concerning the clinical applica-
tion of TachoSil has been published. It concerns a group of 
patients submitted for pancreatic resection with pancrea-
ticojejunal anastomosis protected by TachoSil. The results 
were not statistically significant, but they suggested possible 
advantages of TachoSil use in the prevention of postoperative 
pancreatic fistula.14
Spleen
Benefits of TachoSil application for spleen trauma15 or 
fragile or atraumatic damaged spleen in spleen manage-
ment have been reported.16 In oncohematologic diseases, 
TachoSil may be useful in clotting and for blood composi-
tion disorders.17
Gastrointestinal surgery
Experimental and clinical studies on the sealing of colorec-
tal anastomoses have previously been performed in order 
to reduce the rate of leakage, but with divergent results. 
However, comparatively fewer studies have been performed 
on anastomotic healing using a fibrin glue-coated patch. 
For this reason, an experimental basic scientific study in 
mice investigated the effect of fibrin glue-coated collagen 
patches on the healing process of colonic anastomoses in 
situations of adverse healing processes (technical deficiency 
and peritonitis).18 Colonic anastomoses were carried out in 
206 mice and randomized into six groups from complete 
anastomoses to sealed complete anastomoses in the pres-
ence of bacterial peritonitis. The evaluation of postoperative 
course data revealed the beneficial effect of additional sealing 
with TachoSil in high-risk experimental anastomotic healing. 
Sealing incomplete anastomoses resulted in significantly 
lower lethality and leakage rates.18
A second experimental study analyzed 11 pigs submitted 
to a double intestinal anastomosis treated with and without 
sealing with a collagen patch coated with fibrin glue. The pigs 
were observed for a time variable from 1 week to 6 weeks. 
The observation period was followed by in vivo examina-
tion under general anesthesia. Any difference concerning 
abdominal pathology, in vivo bursting pressure, or degree 
of stenosis was recorded. The collagen fleeces were in situ 
in all anastomoses.19
Surgery for peptic ulcer perforation is one of the most 
common emergency procedures carried out in the Western 
world; however, its mortality risk remains significantly high, 
despite improvement in surgical techniques, anesthesia, and 
critical care. Graham’s patch omentoplasty represents the 
treatment of choice for both open and laparoscopic surgery. 
An experience of the gastric wall being repaired by a full-
thickness suture followed by TachoSil patch application, 
which was finally covered by the classic omental patch, has 
been reported in the literature.20
inguinal hernia repair
TachoSil has been investigated for the treatment of inguinal 
hernia repair. A recently published study examined what 
new absorbable materials can be used in the treatment of 
inguinal hernia with the same efficacy as the traditionally 
used polypropylene mesh. The authors performed an experi-
mental study and a clinical study comparing direct hernia 
repair methods using Lichtenstein’s operation in humans 
after implantation of polypropylene mesh or TachoSil for 
fascia transversalis reinforcement regarding postoperative Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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pain and complications, time needed for patient mobilization, 
and recurrences. Patients implanted with TachoSil had sig-
nificantly lower postoperative pain scores on a visual analog 
scale and used lower doses of analgesic. The overall incidence 
of postoperative complications was significantly reduced 
with the use of TachoSil. The incidence of   recurrences after 
24-month follow-up was the same in both groups. The study 
showed that TachoSil has the same short-term efficacy in 
hernia treatment as the standard polypropylene mesh, with 
a reduction in postoperative pain and analgesic use and a 
decrease in overall postoperative complications.21
Laparoscopy
The use of TachoSil in open abdominal surgery and its 
relevant results have encouraged the use of TachoSil in 
laparoscopic surgery. Unfortunately, its use in laparoscopy 
has not become as popular as it is in open surgery, due to 
the lack of efficacious techniques. Firstly, the passage of the 
patch via the laparoscopic cannula causes the exfoliation of 
the collagen compound due to its fragility. Not only does the 
product come into the abdominal cavity without its integrity 
but also when it comes into contact with blood or fluid, the 
fibrin-coated part is immediately activated and its manipu-
lation becomes very difficult. The patch should be treated 
without touching any organ or fluid, and it should be applied 
accurately the first time. If this passage is made in the wrong 
way, the patch should not be used anymore, and another one 
should be inserted in the abdominal cavity. Moreover, when 
this patch is used to cover the liver surface after hepatic 
resection, pressure cannot be exercised uniformly as in open 
surgery, so a fluid collection can be found between the liver 
surface and the TachoSil in the postoperative period. This 
collection is usually asymptomatic, and no treatment, such 
as external drainage, is needed.
Efficacy and safety
Immunologic reactions to compounds of TachoSil and the 
transmission of infectious diseases are the two major risks 
concerning topical hemostasis. Differently from TachoC-
omb and TachoComb H (both containing material of bovine 
origin), and even though the risk of severe immunologic 
reactions to bovine material is low, TachoSil has gradually 
replaced all bovine material with material of human origin 
and therefore has eliminated the associated risks of bovine 
material. The collagen is derived from horse tendons, which 
could potentially still cause immunological reactions, but 
  collagens generally have low immunogenicity, so immuno-
logic reactions to equine collagen are very unlikely.22
Another risk is the transmission of infectious diseases. 
There is a potential risk of transmission of micro-organisms 
from blood samples that are used to produce TachoSil, 
even if, according to the manufacturer, blood comes only 
from selected donors and all the active measures against 
enveloped viruses are used. Nonenveloped viruses are more 
resistant, especially the parvovirus B19. Infections with 
parvovirus B19 can lead to serious conditions with aplastic 
crisis. This is particularly dangerous for pregnant women, 
so the use of TachoSil is not recommended in pregnancy. 
Even if the risk exists, no reports of parvovirus transmission 
with TachoSil can be found in the literature. Limited data 
exist about the prions that may cause Creutzfeldt–Jakob 
disease. Although prions can be found in blood, there have 
been no reports of transmission by manufactured plasma 
products.
TachoSil has a good satisfaction rate among surgeons and 
reduces both the operating time for patients and time spent 
in intensive care units.23
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